<DOC>
	<DOCNO>NCT02162888</DOCNO>
	<brief_summary>The purpose study demonstrate new formulation Bendamustine ( BDM ) Hydrochloride ( HCl ) bioequivalent ( BE ) ( similar ) commercially available product patient cancer .</brief_summary>
	<brief_title>A Phase I , Bioequivalence Study Evaluate Two Formulations Bendamustine ( BDM ) Hydrochloride ( HCl ) Administered Cancer Patients</brief_title>
	<detailed_description>This open-label , randomize , crossover , Phase I study intend demonstrate BE , safety tolerability profile 2 formulation BDM HCl administer cancer patient : Eagle-BDM Teva-BDM Histologically confirm diagnosis malignant disease ( solid tumor hematologic malignancy eligible ) curative standard therapy appropriate . At end study , patient may enrol open-label extension ( OLE ) study ( Study EGL-BDM-C-1301-OLE ) , discretion investigator .</detailed_description>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically confirm diagnosis malignant disease curative standard therapy appropriate . Bone Marrow Function Blood Chemistry result within protocol limit CLL HIV Presence brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>